Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
1999-01-27
2004-02-10
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S185100, C424S186100, C530S324000, C530S327000, C530S328000
Reexamination Certificate
active
06689363
ABSTRACT:
INDEX
I. Background of the Invention
II. Summary of the Invention
III. Brief Description of the Figures
IV. Detailed Description of the Invention
A. Definitions
B. Stimulation of CTL and HTL responses against HBV
C. Immune Response Stimulating Peptides
1. Binding Affinity of the Peptides for HLA Molecules
2. Peptide Binding Motifs and Supermotifs
a) HLA-A1 supermotif
b) HLA-A2 supermotif
c) HLA-A3 supermotif
d) HLA-A24 supermotif
e) HLA-B7 supermnotif
f) H LA-B27 supermotif
g) HLA-B44 supermotif
h) HLA-B58 supermotif
i) HLA-B62 supermotif
j) HLA-A1 motif
k) HLA-A3 motif
l) HLA-A11 motif
m) HLA-A24 motif
n) HLA-A2.1 motif
o) HLA-DR-1-4-7 supermotif
p) HLA-DR3 motifs
3. Enhancing Population Coverage of the Vaccine
D. Immune Response Stimulating Peptide Analogs
E. Computer Screening of Protein Sequences from Disease-Related Antigens for Supermotif or Motif Containing Peptides
F. Assays to Detect T-Cell Responses
G. Preparation of Peptides
H. Use of Peptide Epitopes for Evaluating Immune Responses
I. Vaccine Compositions
1. Minigene Vaccines
2. Combinations with Helper Peptides
J. Administration of Vaccines for Therapeutic or Prophylactic Purposes
K. Kits
V. Examples
I. BACKGROUND OF THE INVENTION
Chronic infection by hepatitis B virus (HBV) affects at least 5% of the world's population and is a major cause of cirrhosis and hepatocellular carcinoma (Hoofnagle, J.,
N. Engl. J. Med
. 323:337, 1990; Fields, B. and Knipe, D., In:
Fields Virology
2:2137, 1990). The World Health Organization lists hepatitis B as a leading cause of death worldwide, close behind chronic pulmonary disease, and more prevalent than AIDS. Chronic HBV infection can range from an asymptomatic carrier state to continuous hepatocellular necrosis and inflammation, and can lead to hepatocellular carcinoma.
The immune response to HBV is believed to play an important role in controlling hepatitis B infection. A variety of humoral and cellular responses to different regions of the HBV nucleocapsid core and surface antigens have been identified. T cell mediated immunity, particularly involving class I human leukocyte antigen-restricted cytotoxic T lymphocytes (CTL), is believed to be crucial in combatting established HBV infection.
Class I human leukocyte antigen (HLA) molecules are expressed on the surface of almost all nucleated cells. CTL recognize peptide fragments, derived from intracellular processing of various antigens, in the form of a complex with class I HLA molecules. This recognition event then results in the destruction of the cell bearing the HLA-peptide complex directly or the activation of non-destructive mechanisms e.g., the production of interferon, that inhibit viral replication.
Several studies have emphasized the association between self-limiting acute hepatitis and multispecific CTL responses (Penna, A. et al.,
J. Exp. Med
. 174:1565, 1991; Nayersina, R. et al.,
J. Immunol
. 150:4659, 1993). Spontaneous and interferon-related clearance of chronic HBV infection is also associated with the resurgence of a vigorous CTL response (Guidotti, L. G. et al.,
Proc. Natl. Acad. Sci. USA
91:3764, 1994). In all such cases the CTL responses are polyclonal, and specific for multiple viral proteins including the HBV envelope, core and polymerase antigens. By contrast, in patients with chronic hepatitis, the CTL activity is usually absent or weak, and antigenically restricted.
The crucial role of CTL in resolution of HBV infection has been further underscored by studies using HBV transgenic mice. Adoptive transfer of HBV-specific CTL into mice transgenic for the HBV genome resulted in suppression of virus replication. This effect was primarily mediated by a non-lytic, lymphokine-based mechanism (Guidotti, L. G. et al.,
Proc. Natl. Acad. Sci. USA
91:3764, 1994; Guidotti, L. G., Guilhot, S., and Chisari, F. V.
J. Virol
. 68:1265, 1994; Guidotti, L. G. et al.,
J. Virol
. 69:6158, 1995; Gilles, P. N., Fey, G., and Chisari, F. V.,
J. Virol
. 66:3955, 1992).
As is the case for HLA class I restricted responses, HLA class II restricted T cell responses are usually detected in patients with acute hepatitis, and are absent or weak in patients with chronic infection (Chisari, F. V. and Ferrari, C.,
Annu. Rev. Immunol
. 13:29, 1995). HLA Class II responses are tied to activation of helper T cells (HTLs) Helper T lymphocytes, which recognize Class II HLA molecules, may directly contribute to the clearance of HBV infection through the secretion of cytokines which suppress viral replication (Franco, A. et al.,
J. Immunol
. 159:2001, 1997). However, their primary role in disease resolution is believed to be mediated by inducing activation and expansion of virus-specific CTL and B cells.
In view of the heterogeneous immune response observed with HBV infection, induction of a multi-specific cellular immune response directed simultaneously against multiple epitopes appears to be important for the development of an efficacious vaccine against HBV. There is a need to establish vaccine embodiments that elicit immune responses that correspond to responses seen in patients that clear HBV infection. Epitope-based vaccines appear useful.
Upon development of appropriate technology, the use of epitope-based vaccines has several advantages over current vaccines. The epitopes for inclusion in such a vaccine are to be selected from conserved regions of viral or tumor-associated antigens, in order to reduce the likelihood of escape mutants. The advantage of an epitope-based approach over the use of whole antigens is that there is evidence that the immune response to whole antigens is directed largely toward variable regions of the antigen, allowing for immune escape due to mutations. Furthermore, immunosuppressive epitopes that may be present in whole antigens can be avoided with the use of epitope-based vaccines.
Additionally, with an epitope-based vaccine approach, there is an ability to combine selected epitopes (CTL and HTL) and additionally to modify the composition of the epitopes, achieving, for example, enhanced immunogenicity. Accordingly, the immune response can be modulated, as appropriate, for the target disease. Similar engineering of the response is not possible with traditional approaches.
Another major benefit of epitope-based immune-stimulating vaccines is their safety. The possible pathological side effects caused by infectious agents or whole protein antigens, which might have their own intrinsic biological activity, is eliminated.
An epitope-based vaccine also provides the ability to direct and focus an immune response to multiple selected antigens from the same pathogen. Thus, patient-by-patient variability in the immune response to a particular pathogen may be alleviated by inclusion of epitopes from multiple antigens from that pathogen in a vaccine composition. A “pathogen” may be an infectious agent or a tumor associated molecule.
However, one of the most formidable obstacles to the development of broadly efficacious epitope-based immunotherapeutics has been the extreme polymorphism of HLA molecules. To date, effective non-genetically biased coverage of a population has been a task of considerable complexity; such coverage has required that epitopes be used specific for HLA molecules corresponding to each individual HLA allele, therefore, impractically large numbers of epitopes would have to be used in order to cover ethnically diverse populations. There has existed a need to develop peptide epitopes that are bound by multiple HLA antigen molecules for use in epitope-based vaccines. The greater the number of HLA antigen molecules bound, the greater the breadth of population coverage by the vaccine.
Furthermore, as described herein in greater detail, a need has existed to modulate peptide binding properties, for example so that peptides that are able to bind to multiple HLA antigens do so with an affinity that will stimulate an immune response. Identification of epitopes restricted by more than one HLA allele at an affinity that correlates with immunogenicity is important to provide thorough population
Celis Esteban
Chesnut Robert W.
Grey Howard M.
Kubo Ralph T.
Livingston Brian D.
Epimmune Inc.
Housel James
Lucas Zachariah
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Inducing cellular immune responses to hepatitis B virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inducing cellular immune responses to hepatitis B virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inducing cellular immune responses to hepatitis B virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3353486